Company signals
Orion Innovation
1 signal in the current window, with MitchelLake's leadership read on each.
Market context: This lands while the Talent Market Index reads 110 (Hot) — up 11.7 versus the prior month — and Americas signal share is easing (-12.5pts).
Orion Innovation: 1 signal in the last 90 days; 0.1% of MitchelLake's Americas signal flow.
Signals at Orion Innovation
More signals across Americas
Product Launch · Americas
SABIC →SABIC launched NORYL V0150TW and V0150IR2 laser-weldable thermoplastic resins designed for solar microinverters, tracker boxes, and junction boxes. The resins enable shift from ultrasonic welding/adhesive bonding to laser welding, reducing production cycle times and assembly costs by up to 30% material usage reduction and 40% part size reduction.
Product Launch · Americas
Zensar Technologies →Zensar Technologies launched ZenseAI.AgentMesh, an enterprise-grade agentic AI platform designed to help organizations discover, build, and deploy AI solutions at scale.
Product Launch · Americas
Danone →Danone expanded its Silk Protein line with dairy-free yoghurts (13g protein per 6oz serving) and ready-to-drink protein shakes (30g protein per 11.15oz bottle). Yoghurts launching nationwide later this month; shakes rolling out next month across the US.
Product Launch · Americas
Netskope →Netskope released its 2026 Cloud and Threat Report, revealing that nearly 50% of enterprise generative AI users access unsanctioned AI tools through personal accounts, with an average organization reporting 223 AI policy violations monthly. The report identifies shadow AI as adding $670,000 to average breach costs.
Product Launch · Americas
Medtronic →Medtronic received FDA 510(k) clearance in June 2026 for its Nellcor pulse oximetry system with Nell-EQ intelligent processor. Product designed to improve oxygen saturation and pulse rate monitoring accuracy across diverse skin tones and care settings, aligned with new ISO 80601-2-61:2026 standards.
Product Launch · Americas
Neurocrine Biosciences →Neurocrine presented CRENESSITY clinical data at ENDO 2026 demonstrating hormone normalization in classic CAH and two-year cardiometabolic and bone health outcomes in adults.
Intelligence powered by Autonodal ↗